Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study.

Trial Profile

Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza virus infections; Respiratory tract infections
  • Focus Therapeutic Use

Most Recent Events

  • 26 Jul 2013 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
  • 26 Jul 2013 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
  • 17 Oct 2012 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov (NCT01546935).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top